Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Insmed Shares Skyrocket After Lung Drug Meets Key Study’s Main Goal

By Reuters | September 5, 2017

Shares of Insmed Inc more than doubled on Tuesday after the company said its drug to treat adults with a rare lung disorder met the main goal in a key study, leading it to apply for accelerated approval.

Insmed’s shares jumped 140 percent in early trade – their record intraday percentage gain. The U.S. Food and Drug Administration had previously granted the drug breakthrough therapy designation and fast-track status.

“I feel highly confident that the drug will be approved by the FDA in the next 12 months,” Stifel analyst Adam Walsh told Reuters.

“In our model, we see gross price of $60,000 and net price of $48,000 in the U.S. for the drug if it gets approved,” Walsh added.

The inhaled once-daily drug, Alis, was used for the treatment of resistant nontuberculous mycobacterial (NTM) lung infections in a late-stage study that involved 336 adult patients.

The company said the addition of the drug to standard treatment showed statistical significance in reducing bacterial density, a measure of change in infection, by the sixth month in 29 percent of patients, compared with 9 percent in patients on standard treatment alone.

NTM lung infections are caused by a type of bacteria found in soil as well as water and are characterized by cough, fever and blood in the mucus. There is no approved treatment for the infections.

The company, which expects Japan as one of its key markets for Alis, said it plans to hold discussions with Japanese regulators in the first half of 2018 for the drug’s approval.

Insmed is developing several other lung disease treatments. Its drug, Arikayce, is being tested in late stage, while others are in their early stages.

The company’s stock, which touched a more than 11-year high of $29.52, was the third-most actively traded on the Nasdaq.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE